Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells
Related Experiment Video
Updated: Oct 16, 2025
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
Published on: February 2, 2024
Melita Irving1, Evripidis Lanitis1, Denis Migliorini2,3,4
1Department of Oncology, Ludwig Institute for Cancer Research Lausanne, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Abstract:
T cell modification with genes that encode chimeric antigen receptors (CAR-T cells) has shown tremendous promise for the treatment of B cell malignancies. The successful translation of CAR-T cell therapy to other tumor types, including solid tumors, is the next big challenge. As the field advances from second- to next-generation CAR-T cells comprising multiple genetic modifications, more sophisticated methods and tools to engineer T cells are being developed. Viral vectors, especially γ-retroviruses and lentiviruses, are traditionally used for CAR-T cell engineering due to their high transduction efficiency. However, limited genetic cargo, high costs of production under good manufacturing practice (GMP) conditions, and the high regulatory demands are obstacles for widespread clinical translation. To overcome these limitations, different nonviral approaches are being explored at a preclinical or clinical level, including transposon/transposase systems and mRNA electroporation and nonintegrating DNA nanovectors. Genome editing tools that allow efficient knockout of particular genes and/or site-directed integration of the CAR and/or other transgenes into the genome are also being evaluated for CAR-T cell engineering. In this review, we discuss the development of viral and nonviral vectors used to generate CAR-T cells, focusing on their advantages and limitations. We also discuss the lessons learned from clinical trials using the different genetic engineering tools, with special focus on safety and efficacy.
Insights
Chimeric antigen receptor T cell (CAR-T) therapy shows promise for B cell cancers. New viral and nonviral methods are being developed to improve CAR-T cell engineering for broader applications, including solid tumors.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized B cell malignancy treatment.
- Translating CAR-T therapy to solid tumors and next-generation modifications presents significant challenges.
- Current T cell engineering relies heavily on viral vectors, posing production and regulatory hurdles.
Purpose of the Study:
- To review the development of viral and nonviral vectors for CAR-T cell engineering.
- To analyze the advantages and limitations of different genetic engineering tools.
- To discuss clinical trial outcomes, focusing on safety and efficacy.
Main Methods:
- Review of viral vectors (γ-retroviruses, lentiviruses) and nonviral approaches (transposons, mRNA electroporation, DNA nanovectors).
- Evaluation of genome editing tools for gene knockout and site-directed integration.
- Analysis of data from clinical trials employing various genetic engineering strategies.
Main Results:
- Viral vectors offer high transduction efficiency but face limitations in cargo capacity, cost, and regulation.
- Nonviral methods and genome editing tools are emerging as promising alternatives to overcome viral vector constraints.
- Clinical trials highlight the importance of engineering tool selection for CAR-T cell safety and efficacy.
Conclusions:
- Advancements in both viral and nonviral vector technologies are crucial for expanding CAR-T cell therapy applications.
- Optimizing T cell engineering methods is key to improving the safety and efficacy of CAR-T cell treatments for diverse cancers.
- Continued research into novel delivery systems and genome editing is essential for the future of CAR-T cell therapy.
More Related Videos
06:10Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019